학술논문
Preclinical characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder
Document Type
Article
Author
Bristow, L.J.; Weed, M.R.; Li, Y.-W.; Graef, J.D.; Molski, T.; Pieschl, R.; Fernandes, A.; Brown, J.M.; Sivarao, D.V.; Newberry, K.; Bookbinder, M.; Polino, J.; Keavy, D.; Newton, A.; Albright, C.F.; Bronson, J.J.; Olson, R.E.; Macor, J.E.; King, D.; Thompson, L.A.; Marcin, L.R.; Shields, E.; Simmermacher, J.; Sinz, M.; Kempson, J.; Li, J.; Zhang, H.; Mathur, A.; Gulia, J.; Srikumar, B.N.; Naidu, P.S.; Sanmathi, C.; Aher, J.; Bastia, T.; Paschapur, M.; Kalidindi, N.; Kumar, K.V.; Kallem, R.R.; Sinha, M.; Ramarao, M.; Vikramadithyan, R.K.; Thangathirupathy, S.; Warrier, J.; Islam, I.
Source
In: Journal of Pharmacology and Experimental Therapeutics . (Journal of Pharmacology and Experimental Therapeutics, December 2017, 363(3):377-393)
Subject
Language
English
ISSN
15210103
00223565
00223565